20-30% of patients experiencing relapse after first-line treatment
Standard of care therapies for DLBCL have suboptimal results, with 20-30% of patients experiencing relapse after first-line treatment. Additionally, existing therapies may cause serious adverse events such as cytokine release syndrome.
Bantam Pharmaceuticals is developing an IND-cleared candidate, BNTM-3566, which takes advantage of a DLBCL-specific vulnerabilities to activate cellular stress and tumor apoptosis pathways.
USD 5B market
Bantam Pharmaceuticals is initially targeting the DLBCL market, which has a total market opportunity of ~$5B.
"We are excited to see how BTM-3566 promoted complete tumor regression in vivo in mouse models with poor prognosis. We believe BTM-3566's mechanism of action potentially defines a new class of compounds that activate, and regulate, the mitochondrial protease OMA1.”
Adrian Schwarzer, M.D., Ph.D (Resident at the Department of Hematology, Oncology and Stem Cell Transplantation, Hannover Medical School)
Get in touch
Contact us for more information about how we can help you invest in healthcare, biotech, climate tech, or advanced systems.